Accredited Industry-Supported Symposium: Defining the Future of Autologous Wound Care: Clinical Evidence, Reimbursement, and Practice Integration of a Multilayered Leukocyte, Platelet, and Fibrin Patch

HMP Education has designated an unrestricted grant from Reapplix.

Learning Objectives:
1. Interpret clinical evidence and real-world retrospective outcomes data on the use of an autologous multilayered leukocyte, platelet, and fibrin patch for hard-to-heal wounds and differentiate this patient-derived, point-of-care technology from other autologous blood-derived products.
2. Demonstrate how an autologous multilayered leukocyte, platelet, and fibrin patch can be efficiently incorporated into existing clinic workflows without disruption while maintaining operational efficiency in outpatient wound care practice.
3. Assess reimbursement pathways, coverage considerations, and documentation requirements for the use of an autologous multilayered leukocyte, platelet, and fibrin patch in the office or outpatient wound care setting.
4. Evaluate where an autologous multilayered leukocyte, platelet, and fibrin patch fits within the overall wound care treatment armamentarium, and consider whether a patient biology-derived therapy should be used as a first-line option for chronic wounds.
5. Explore real-world case studies of chronic wounds treated in the office or outpatient wound care setting with an autologous multilayered leukocyte, platelet, and fibrin patch.